

# Jordan M Chinai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9775784/publications.pdf>

Version: 2024-02-01

9  
papers

993  
citations

1040056  
9  
h-index

1474206  
9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

1625  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. <i>Scientific Reports</i> , 2016, 6, 30093.	3.3	213
2	HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9879-9884.	7.1	160
3	New immunotherapies targeting the PD-1 pathway. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 587-595.	8.7	158
4	Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. <i>Clinical Cancer Research</i> , 2015, 21, 2359-2366.	7.0	125
5	HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. <i>OncolImmunology</i> , 2015, 4, e1026534.	4.6	93
6	HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status. <i>Clinical Cancer Research</i> , 2017, 23, 825-832.	7.0	78
7	HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. <i>Scientific Reports</i> , 2016, 6, 31154.	3.3	69
8	Structure and Cancer Immunotherapy of the B7 Family Member B7x. <i>Cell Reports</i> , 2014, 9, 1089-1098.	6.4	58
9	KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. <i>Science Immunology</i> , 2021, 6, .	11.9	39